NEW YORK, Feb. 1, 2021 /PRNewswire/ --
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]
NantKwest, Inc. (NASDAQ: NK)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NantKwest, Inc. (NASDAQ: NK) in connection with the company's proposed merger with ImmunityBio. Under the terms of the merger agreement, NantKwest will acquire ImmunityBio through a reverse merger pursuant to which, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. If you own NK shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/nk/
Xilinx, Inc. (NASDAQ: XLNX)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Xilinx, Inc. (NASDAQ: XLNX) in connection with the proposed acquisition of the company by Advanced Micro Devices, Inc. ("AMD"). Under the terms of the agreement, XLNX shareholders will receive 1.7234 shares of AMD common stock for each XLNX share that they own, representing implied per-share merger consideration of $147.59 based upon AMD's January 29, 2021 closing price of $85.64. If you own XLNX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/xlnx/
GX Acquisition Corp. (NASDAQ: GXGX)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GX Acquisition Corp. (NASDAQ: GXGX) in connection with the company's proposed merger with Celularity Inc. ("Celularity"). Under the terms of the merger agreement, GXGX will acquire Celularity through a reverse merger that will result in Celularity becoming a publicly listed company. If you own GXGX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/gxgx/
ACE Convergence Acquisition Corp. (NASDAQ: ACEV)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ACE Convergence Acquisition Corp. (NASDAQ: ACEV) in connection with the company's proposed merger with Achronix Semiconductor Corporation ("Achronix"). Under the terms of the merger agreement, ACEV will acquire Achronix through a reverse merger that will result in Achronix becoming a publicly listed company. The transaction reflects an implied equity value of the combined company of $2.1 billion. If you own ACEV shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/acev/
SOURCE WeissLaw LLP
![](https://rt.prnewswire.com/rt.gif?NewsItemId=DC66191&Transmission_Id=202102011902PR_NEWS_USPR_____DC66191&DateId=20210201)
Share this article